The Cancer Letter

Inside information on cancer research and drug development

COVID-19 & Cancer

NCI steps in to pay trainees whose funding from nonprofits fails to materialize

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Our full coverage of SARS-CoV2 is available here.

If non-profit organizations are unable to make good on their commitments to trainees, NCI is prepared to fill that gap, NCI Director Ned Sharpless said during a July 22 virtual meeting of the American Association for Cancer Research on COVID-19 and Cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account